Introduction to Sanofi and Genzyme

Size: px
Start display at page:

Download "Introduction to Sanofi and Genzyme"

Transcription

1 Introduction to Sanofi and Genzyme 495/MetroWest Partnership's Conference Panel December 15, 2015 Michelle Multiple Sclerosis Denmark

2 Overview Who is Sanofi? Who is Genzyme MetroWest Investment Talent Real Estate Community Relations 2

3 Who is Sanofi? Sanofi is a global healthcare leader focused on patients needs: engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. 4 th largest pharmaceutical group in the world Headquartered in France 3

4 SANOFI AT A GLANCE More than 110,000 employees Present in 100 countries Our mission We act with our partner to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the word. 3 Commitments Exploring the boundaries of medical innovation for patients Preventing disease and supporting patients Improving access to healthcare 33.8 million In sales business segments Pharma Human vaccines Animal Health CORPORATE PRESENTATION

5 PHARMA HUMAN VACCINES ANIMAL HEALTH SANOFI AT A GLANCE OUR 3 BUSINESS SEGMENTS > Diabetes > Cardiovascular disease > Rare diseases > Multiple sclerosis > Oncology > Consumer Health care > Generics > Pediatric vaccines > Influenza vaccines > Booster vaccines for adults and adolescents > Meningitis vaccines >Vaccines for travelers and endemic areas PHARMA PRODUCTS > Anti-parasitics > Anti-infectives > Anti-inflammatories > Anti-ulceratives VACCINES > Foot and mouth disease > Rabies and pets vaccines Range > Avian vaccines Net sales 27,720 M Net sales 3,974 M Net sales 2,076 M G. Blonsky/Capa Pictures CORPORATE PRESENTATION

6 GROWTH PLATFORMS Emerging markets Diabetes solutions Vaccines Consumer Healthcare Animal Health Genzyme Other Innovative Products 33.8 million In sales in Industrial sites in 41 countries present in more than 100 countries more than employees R&D A major biopharmacy player 45% of revenues generated by biologics 80% of development projects are biologics Information of December 31 st 2013

7 Who is Genzyme? A pioneer of the biotechnology movement in the early 1980s, Genzyme has always been driven by cutting-edge science and a commitment to treating unmet medical needs. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). We have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis 7 Generated 2,604 million in Sales for 2014, an increase of 24%

8 Rare Diseases Lysosomal Storage Disorders (LSDs) are the cornerstone of Genzyme's rare disease business Leverage our legacy to expand our expertise in additional therapeutics areas Innovative partnership with Alnylam focused on RNAi Sol Pompe disease Eva & Alberto Fabry disease THEREAPEUTIC AREAS Hematology Nephrology Neurology Pediatric Endocrinology Other TREATMENT AREAS Gaucher disease type 1 Pompe disease MPS I & II disease Fabry disease Thyroid cancer Homozygous Familial Hypercholesterolemia

9 Multiple Sclerosis Shani MS Tiger MS Once-daily oral therapy for relapsing remitting MS Infusion therapy for relapsing remitting MS 2 annual treatment courses MS business unit launched with the approval of two new therapies in 2013 Unique, personalized approach to patient care Strong early-stage MS pipeline focused on targeted immunomodulation, neuroprotection, remylenation, and progressive MS

10 MA Landscape: Genzyme s Impact Sanofi Genzyme is the largest Bio-Pharma employer in Massachusetts, with a combined 5,000 Sanofi Genzyme employees. Genzyme consistently ranks as one of the top charitable companies in Massachusetts, leading the Bio-Pharma industry. Genzyme s footprint stretches beyond the traditional center of Kendall Square, with sites in Allston, Framingham, Westborough and Northborough. 10

11 Sanofi Genzyme MetroWest Facts! Located in 19 buildings 2300 full time employees Real estate capacity to support an additional ~1100 employees Dedicated R&D Center and Manufacturing Operations Top 3 sources of talent finding: Internal Referral Direct Filled ~370 of the ~540 open positions

12

13 Genzyme Northborough Operation Center (gnoc) Located in Northborough, Massachusetts Nearly 20 Acres of property with a 20 year lease. Over 200,000 square feet of warehouse space, fully equipped to meet the growth of Genzyme and meeting Quality standards Approximately 200 employees 13

14 gnoc Facts Total Size: 254,095 sq ft 2 TSA Certified Cargo Screening Areas 24/7 Full-Perimeter Security 2 Megawatt Diesel Backup Generator Materials Operations Warehouse 134,813 sq ft CRT 4,350 pallets 2-8C 791 pallets -20C 316 pallets Receiving 9 docks Shipping 6 docks Offices 1,202 sq ft Clinical Supplies Warehouse CRT Offices 10,160 sq ft 654 pallets 5,923 sq ft Quality Control Raw Materials Warehouse 10,197 sq ft CRT 480 pallets Lab 3,200 sq ft Sampling suite 2,000 sq ft Office 4,326 sq ft Labeling & Packaging GroupPackaging Suite 9,194 sq ft 2-8C 500 sq ft Offices 5,923 sq ft 14

15 Cerezyme Fabrazyme Myozyme / Lumizyme Clolar Thyrogen Aldurazyme Elaprase SepraFilm LeGoo Hyaluronic Acid (HA) Materials Support

16 Genzyme in Westborough Moved into One Research Drive from Framingham on November 21, employees working across multiple functions: Genzyme Industrial Operations Global Leadership and support functions Genzyme Corporate Quality Operations and Global Quality Leadership Sanofi Information Solutions Sanofi Human Resources (including Staffing) Sanofi Regulatory Affairs and Procurement Employee Volunteerism

17 Community Relations Our Community Relations mission is to have a lasting positive impact where our employees live and work, by building sustainable partnerships through a combination of financial contributions and employee involvement. Employee Volunteerism Health+ Access Good Neighbors Science Education

18 Dedicated and Committed Community Relations Mission in MetroWest! In 2014, Genzyme awarded ~$125,000 in grants/sponsorships to MetroWest Organizations Genzyme Science Kids program at Fuller Middle School Boys and Girls Club of MetroWest Big Brothers Big Sisters of Central Mass MetroWest Community Farms Outreach Family Promise MetroWest Framingham Public Library Habitat for Humanity of MetroWest/Worcester MetroWest Free Medical Program Ashland Fire Department Association 18

19 19 Thank You!

SOL, ARGENTINA POMPE DISEASE. This is Genzyme

SOL, ARGENTINA POMPE DISEASE. This is Genzyme SOL, ARGENTINA POMPE DISEASE This is Genzyme MARIA, GAUCHER DISEASE TONY, FABRY DISEASE MICHELLE, MULTIPLE SCLEROSIS BRANT, THYROID CANCER JIMENA, MPS I GENZYME Genzyme has pioneered the development and

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services

Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Providing a wide range of clinical research services Abt Associates Clinical Trials (AACT) is dedicated to providing

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Cegedim Half-year results 2009 September 2009

Cegedim Half-year results 2009 September 2009 Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849

More information

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,

More information

ZENTIVA A SANOFI COMPANY. Corporate Presentation

ZENTIVA A SANOFI COMPANY. Corporate Presentation ZENTIVA A SANOFI COMPANY Corporate Presentation SANOFI A global healthcare leader, focused on patients needs SANOFI A global integrated healthcare leader, focused on patients needs CORPORATE PRESENTATION

More information

Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right Sanofi-aventis Genzyme Media Contact : Media Contact : Jean-Marc Podvin Bo Piela +33 1 53 77 44 50 617-768-6579 508-308-9783 Investor Contact : Investor Contact : Sébastien Martel Patrick Flanigan +33

More information

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer putting ideas to work March 2007 Dr. Rob Whitehead Associate Director, Office of Technology Transfer March 2008 Research Extensive, Land-grant

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

Life Sciences Outlook. Boston 2015

Life Sciences Outlook. Boston 2015 Life Sciences Outlook Boston 2015 Greater Boston Greater Boston possesses the largest concentration of life science researchers in the United States and has over 3.75 million square feet of requirements.

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease

Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview

More information

Creating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres

Creating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres Creating Joint Value In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century By Ben Gomes-Casseres 36 STRATEGIC ALLIANCE MAGAZINE Q3 2014 Look at any of your alliances. How do you

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento

More information

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute

A Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute A Texas Life Science Perspective Thomas R. Kowalski President Texas Healthcare and Bioscience Institute 1 What is THBI? The Texas Healthcare and Bioscience Institute (THBI) is a non-profit, public policy

More information

Delcin Consulting Group

Delcin Consulting Group Delcin Consulting Group 1375 Locust Street, Suite 200, Walnut Creek, CA 94596 Phone: 925-276-2095 Fax: 925-276-2096 Email: info@delcinconsulting.com Website: www.delcinconsulting.com All Rights Reserved,

More information

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award 2015 Russian Nanotechnology Investment Enabling Technology Leadership Award 2015 Contents Background and Company Performance... 3 Technology Leverage and Customer Impact of OJSC RUSNANO... 3-5 Conclusion...

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

LifeScience Logistics Achieves 99.97% Inventory Accuracy With TECSYS EliteSeries for Healthcare

LifeScience Logistics Achieves 99.97% Inventory Accuracy With TECSYS EliteSeries for Healthcare TECSYS Customer Success Story LifeScience Logistics Achieves 99.97% Inventory Accuracy With TECSYS EliteSeries for Healthcare With TECSYS we have a reliable IT infrastructure that can be tapped anytime,

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

Life Sciences Outlook. New Jersey 2015

Life Sciences Outlook. New Jersey 2015 Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Medical Equipment Monthly Deals Analysis: January 2015- M&A and Investment Trends

Medical Equipment Monthly Deals Analysis: January 2015- M&A and Investment Trends Medical Equipment Monthly Deals Analysis: January 2015- M&A and Investment Trends Reference Code: GDME0470MD Publication Date: March 2015 Independent Medical Equipment Research M&A Trends and Analysis

More information

Sector Analysis February 4, 2016

Sector Analysis February 4, 2016 Sector Analysis Analysis of Orphan Drug Market There is significant interest among drug makers and investors alike to focus on the development of products for orphan indications. The reason is these drugs

More information

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Erin-Marie Beals Phone 1-781-681-2850 September 9, 2014 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data include

More information

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead?

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? TAILORED TO THE INDUSTRY FLEXIBLE BUT CONSISTENT UNIQUE DELIVERY CROSS INDUSTRY NETWORKING THE ECBLS MEANS

More information

PEDIATRIC MEDICINES: GLOBAL MARKETS

PEDIATRIC MEDICINES: GLOBAL MARKETS PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical

More information

Technology and Expertise Add Operational Value to Medical Device Trials

Technology and Expertise Add Operational Value to Medical Device Trials Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks

More information

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory

More information

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to

More information

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of September 10, 2014 Contact: Shikha Virdi 905-919-0200 ext. 5504 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data

More information

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act) Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and

More information

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion...

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion... Contents Background and Company Performance... 3 Industry Challenges... 3 Product Family Attributes and Business Impact... 3 Conclusion... 5 Significance of Product Leadership... 6 Understanding Product

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

Deals Profiled. M&A Activity. Sector Acquirer Target. In this Issue: M&A Snapshot Information Technology Medical Devices Biotechnology Pharmaceuticals

Deals Profiled. M&A Activity. Sector Acquirer Target. In this Issue: M&A Snapshot Information Technology Medical Devices Biotechnology Pharmaceuticals In this Issue: M&A Snapshot Information Technology Medical Devices Biotechnology Pharmaceuticals Deals Profiled Sector Healthcare-IT Intuit Medfusion Biotechnology PerkinElmer, Inc. Signature Genomics

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

Medical & Surgical Devices for Children: MDUFA IV Public Meeting. July 13, 2015. Tamar Magarik Haro Associate Director Dept. of Federal Affairs

Medical & Surgical Devices for Children: MDUFA IV Public Meeting. July 13, 2015. Tamar Magarik Haro Associate Director Dept. of Federal Affairs Medical & Surgical Devices for Children: MDUFA IV Public Meeting July 13, 2015 Tamar Magarik Haro Associate Director Dept. of Federal Affairs American Academy of Pediatrics The American Academy of Pediatrics

More information

METROWEST MEDICAL CENTER

METROWEST MEDICAL CENTER (508) 650-7000 Framingham Union METROWEST MEDICAL CENTER 115 Lincoln Street (508) 383-1000 24-hour Emergency Department Care Community Healthcare Provider This healthcare network encompasses the entirety

More information

Specialty Pharmacy? Disclosure. Objectives Technician

Specialty Pharmacy? Disclosure. Objectives Technician Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University

More information

Children's Hospital Boston - Strategic SWOT Analysis Review

Children's Hospital Boston - Strategic SWOT Analysis Review Brochure More information from http://www.researchandmarkets.com/reports/1837823/ Description: Summary Children's Hospital Boston (Children s) is the pediatric medical center that provides a full range

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Treating Refractory Hematological Malignancies Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

Treating Refractory Hematological Malignancies Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics Brochure More information from http://www.researchandmarkets.com/reports/2635096/ Treating Refractory Hematological Malignancies Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging

More information

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts

More information

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

LEARN MORE AT: www.aroc.org. AROC puts DO Physicians within your reach!

LEARN MORE AT: www.aroc.org. AROC puts DO Physicians within your reach! MARKETING GUIDE LEARN MORE AT: AROC puts DO Physicians within your reach! AROC is hosted annually by the New Jersey Association of Osteopathic Physicians and Surgeons (NJAOPS). Founded in 1901, NJAOPS

More information

Inviting Possibilities. Healthcare. Cover Page- Healthcare Sector Report.indd 1

Inviting Possibilities. Healthcare. Cover Page- Healthcare Sector Report.indd 1 Inviting Possibilities Healthcare Cover Page- Healthcare Sector Report.indd 1 7/30/13 1:4 PM TABLE OF CONTENTS Overview of Dubai's Healthcare Industry Investment opportunities Medical research and development

More information

Inventory of Access and Prices of Orphan Drugs across Europe:

Inventory of Access and Prices of Orphan Drugs across Europe: www.eurordis.org Inventory of Access and Prices of Orphan Drugs across Europe: A Collaborative Work between National Alliances on Rare Diseases & Eurordis Yann Le Cam Chief Executive Officer, EURORDIS

More information

MSC IN MEDICINAL CHEMISTRY

MSC IN MEDICINAL CHEMISTRY faculty of health and medical sciences university of copenhagen MSC IN MEDICINAL CHEMISTRY det sundhedsvi københavns univer Master s programme at the University of Copenhagen msc in medicinal chemistry

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Industry NHS data sharing for collaborative product development

Industry NHS data sharing for collaborative product development Industry NHS data sharing for collaborative product development Changing strategies in clinical evidence gathering: Are randomised, doubleblinded studies to become extinct? The RCT is not extinct, but

More information

From Research Services and Process Development to GMP Manufacturing

From Research Services and Process Development to GMP Manufacturing From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development

More information

Annual India Healthcare Excellence Awards 2015. October 9, 2015 Hyatt Regency Hotel, Mumbai

Annual India Healthcare Excellence Awards 2015. October 9, 2015 Hyatt Regency Hotel, Mumbai Annual India Healthcare Excellence Awards 2015 O V E R V I E W After six successful editions, Frost & Sullivan proudly presents its 7th edition of the India Healthcare Excellence Awards 2015 on Friday,

More information

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015 Brochure More information from http://www.researchandmarkets.com/reports/3293079/ Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015 Description: Relapsing Remitting Multiple Sclerosis

More information

Around the Corner or Around the World

Around the Corner or Around the World Around the Corner or Around the World Worldwide logistical support 24/7/365. Mission Statement Cavalier Logistics aims to provide the highest quality freight forwarding services to our customers, by being

More information

Chapter: 2 Health care Industry in India

Chapter: 2 Health care Industry in India Chapter: 2 Health care Industry in India 2.1 Health care Environment in India Indian healthcare industry, unlike other industries, stands untouched by recession. There had been a steady growth in this

More information

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission

Clinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The

More information

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We

More information

LOCATION & SCOPE EMPLOYEES/PHYSICIANS/ RESEARCHERS/FACULTY

LOCATION & SCOPE EMPLOYEES/PHYSICIANS/ RESEARCHERS/FACULTY LOCATION & SCOPE The LMA is located on a 213-acre site, three miles southwest of downtown Boston, adjacent to the neighborhoods of the Fenway, Mission Hill, Audubon Circle and the Town of Brookline. The

More information

ELITech Group - Product Pipeline Analysis

ELITech Group - Product Pipeline Analysis Brochure More information from http://www.researchandmarkets.com/reports/2351170/ ELITech Group - Product Pipeline Analysis Description: Summary The Elitech Group (Elitech Group) is a medical device company,

More information

VNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City. Roberta Brill Vice President, VNS Health Plans

VNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City. Roberta Brill Vice President, VNS Health Plans VNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City Roberta Brill Vice President, VNS Health Plans VNS CHOICE Organization Subsidiary of the Visiting Nurse Service of New York

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

Oncology Spotlight Early Commercialization Case Study. Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions

Oncology Spotlight Early Commercialization Case Study. Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions Oncology Spotlight Early Commercialization Case Study Susie Newton RN, MS, AOCN, AOCNS: Senior Director Quintiles Health Management Solutions Objectives Demonstration of the need for early commercialization

More information

ACCELERATING BIOTECHNOLOGY INNOVATION

ACCELERATING BIOTECHNOLOGY INNOVATION ACCELERATING BIOTECHNOLOGY INNOVATION FOR RARE DISEASES: Challenges and solutions Emil D. Kakkis, M.D., Ph.D. President and Founder, EFRD Also CEO, Ultragenyx Pharmaceutical Inc. April 17, 2013 1 EveryLife

More information

Healthcare, Regulatory and Reimbursement Landscape - Australia

Healthcare, Regulatory and Reimbursement Landscape - Australia Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape

More information

Overview of the Specialty Drug Trend

Overview of the Specialty Drug Trend WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory

More information

Center for Life Science Boston Pfizer Center for Therapeutic Innovation

Center for Life Science Boston Pfizer Center for Therapeutic Innovation Center for Life Science Boston Pfizer Center for Therapeutic Innovation CENTER FOR LIFE SCIENCE BOSTON The Center for Life Science Boston is the first of its kind in the country - a speculative, privately-owned,

More information

Opportunities for Emerging Vaccine Markets

Opportunities for Emerging Vaccine Markets Opportunities for Emerging Vaccine Markets Dr. Suresh Jadhav Executive Director Serum Institute of Limited Maharashtra,, 411028 ssj@seruminstitute.com 12 13 March 2014, Brussels Outline Immunization landscape

More information

BIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life.

BIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life. MASTER OF SCIENCE BIOTECHNOLOGY Networked for Success. Networked for Industry. Networked for Life. Bouvé College of Health Sciences College of Science Northeastern s Biotechnology Masters program synthesizes

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

PlantForm Corporation

PlantForm Corporation PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more

More information

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management OCTOBER 5-6, 2015 PARIS, FRANCE 6 th EDITION THE LEADING PARTNERING MEETING IN OPEN INNOVATION FOR LIFE SCIENCES CONFERENCES EXHIBITION HALL ONE-ON-ONE PARTNERING MEETINGS NETWORKING Open PRELIMINARY PROGRAM

More information

MEDICAL DEVICE & DIAGNOSTICS

MEDICAL DEVICE & DIAGNOSTICS to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,

More information

Rutgers Mini-MBA : BioPharma Innovation

Rutgers Mini-MBA : BioPharma Innovation Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation

More information

ACINO SWITZERLAND. Delivering Health Ensuring Effective Relief

ACINO SWITZERLAND. Delivering Health Ensuring Effective Relief ACINO SWITZERLAND Delivering Health Ensuring Effective Relief Content CEO Letter 03 Acino at a glance 05 Our brand»acino Switzerland«06 Commercial Operations 08 Out-licensing 10 Contract Manufacturing

More information

THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS

THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS I. Mission: Seton Hall Law School, Sciences Po, and ETHICS - the International Society of Healthcare Ethics and Compliance Professionals,

More information

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial

More information

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of

More information

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry

STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators

More information

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system

More information

NEUROSCIENCE. THE POWER OFxTM. Experts. Experience. Execution. Medpace Neuroscience Expertise. medpace.com

NEUROSCIENCE. THE POWER OFxTM. Experts. Experience. Execution. Medpace Neuroscience Expertise. medpace.com THE POWER OFxTM Experts. Experience. Execution. Medpace Neuroscience Expertise As a best-in-class strategic partner for sponsors in neuroscience drug and device development, Medpace utilizes key industry

More information

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS

More information

Administrative Organization

Administrative Organization PATIENT DATA AND PATIENT REGISTRIES IN CENTRAL & EASTERN EUROPE Patient Registries as an Opportunity in Bosnia Herzegovina for Access to Medicines Speaker: Tarik Catic, MScPharm, PhD (c), President, ISPOR

More information

Making healthcare run more effectively

Making healthcare run more effectively Making healthcare run more effectively Client-Focused As a company based on values that are client-focused, LifeScience Logistics operates on the premise that we serve our clients, and will do whatever

More information

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Juan Jenny Li works as a chemistry professional at Novo Nordisk s research centre in Beijing Diabetes Protein Technologies

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities

More information

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute

More information